Real Labs, Actual Decisions With Actionable Six Sigma Metrics
Rhea-AI Summary
QuidelOrtho (NASDAQ: QDEL) has announced a featured session at the upcoming Association for Diagnostics & Laboratory Medicine (ADLM) meeting, focusing on Six Sigma metrics in laboratory performance. The session, titled "Real Labs, Real Decisions with Actionable Six Sigma Metrics," will take place on July 29, 2025 at the McCormick Convention Center in Chicago.
The panel discussion will feature experts including Dr. Jared Jaeger as moderator, along with distinguished professionals from the University of Florida PathLab, St. Peter's University Hospital, and UHS Hospitals. The session will explore how QuidelOrtho's Six Sigma tools and real-world laboratory data can be utilized to enhance quality outcomes in clinical settings.
Positive
- None.
Negative
- None.
QuidelOrtho Announces Featured ADLM Session
ADLM Session Details:
Session Title: | Real Labs, Real Decisions with Actionable Six Sigma Metrics |
When: | Tuesday, July 29, 2025 |
Where: | McCormick Convention Center Exhibit Hall, Theater 1 |
Time: | 2:45 p.m. – 3:45 p.m. CT |
Registration: | Space is limited. ADLM attendees can register for the session using |
Real Labs, Real Decisions With Actionable Six Sigma Metrics Panelists:
Dr. Jared Jaeger
Clinical Science Liaison
QuidelOrtho
Moderator
Dr. Bremansu Osa-Andrews
Medical Director of Clinical
Chemistry and Clinical Assistant Professor
University of Florida PathLab
Gilles Attipoe
Director of Laboratory Services
Angela Armato
Core Lab Manager
United Health Services and UHS Hospitals
To learn more about Six Sigma and the value of using real-world data listen to "Sigma Metrics and the Value of Real World Evidence." In this podcast, QuidelOrtho data scientist Johanna Miller discusses how Six Sigma metrics are being adapted for the clinical laboratory.
Unable to attend ADLM? Register to watch a recording of the session: https://www2.na-ma.quidelortho.com/25-adlm-workshop-subscribe.
About QuidelOrtho
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.
Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed–from home to hospital, lab to clinic.
Building on its long history of innovation, QuidelOrtho works with global healthcare customers to advance diagnostics, where insights and solutions seamlessly connect, illuminating a clearer path for informed decisions.
Investor Contact: Juliet Cunningham Vice President, Investor Relations | Media Contact: D. Nikki Wheeler Senior Director, Corporate Communications |
View original content to download multimedia:https://www.prnewswire.com/news-releases/real-labs-actual-decisions-with-actionable-six-sigma-metrics-302507241.html
SOURCE QuidelOrtho Corporation